Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma

British Journal of Cancer

Volumn 99, Issue 8, 2008, Pages 1256-1264

  Fens, M H A M ^a   Hill, K J ^b   Issa, J ^a   Ashton, S E ^b   Westwood, F R ^b   Blakey, D C ^b   Storm, G ^a   Ryan, A J ^b   Schiffelers, R M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Drug targeting; Endothelium; Liposomes; Vascular disrupting agents

Indexed keywords

N ACETYLCOLCHINOL PHOSPHATE; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSOMES; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; TISSUE DISTRIBUTION; UMBILICAL VEINS;

EID: 53849084782     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604675     Document Type: Article

References (41)

1. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303: 1818-1822
2. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24: 1491-1498
3. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ (2002a) ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54: 1497-1502
4. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002b) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974-1983
5. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
6. Drixler TA, Borel Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE (2000) Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 60: 1761-1765
7. Du H, Chandaroy P, Hui SW (1997) Grafted poly-(ethylene glycol) on lipid surfaces inhibits protein adsorption and cell adhesion. Biochim Biophys Acta 1326: 236-248
8. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA (2004) Cardiac safety of liposomal anthracyclines. Semin Oncol 31: 161-181
9. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
10. Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS (2002) High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62: 6371-6375
11. Gould S, Westwood FR, Curwen JO, Ashton SE, Roberts DW, Lovick SC, Ryan AJ (2007) Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Inst 99(22): 1724-1728
12. Hill SA, Chaplin DJ, Lewis G, Tozer GM (2002a) Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer 102: 70-74
13. Hill SA, Toze GM, Pettit GR, Chaplin DJ (2002b) Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 22: 1453-1458
14. Lee SH, Starkey PM, Gordon S (1985) Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80. J Exp Med 161: 475-489
15. Lippert III JW (2006) Vascular disrupting agents. Bioorg Med Chem 15: 605-615
16. McIntyre DJ, Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Blakey DC, Peers IS, Waterton JC (2004) Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 h in the GH3 prolactinoma rat tumor model. Neoplasia 6: 150-157
17. Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, Boerman OC, Storm G (2003) Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 48: 2059-2066
18. Miller CR, Bondurant B, McLean SD, McGovern KA, O'Brien DF (1998) Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37: 12875-12883
19. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592
20. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16: 2445-2451
21. Park JW (2002) Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4: 95-99
22. Pattillo CB, Sari-Sarraf F, Nallamothu R, Moore BM, Wood GC, Kiani MF (2005) Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res 22: 1117-1120
23. Perez AT, Domenech GH, Frankel C, Vogel CL (2002) Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest 20(Suppl 2): 22-29
24. Radema SA, Beerpoot LV, Witteveen PO, Gebbink MF, Wheeler C, Voest EE (2002) Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage. Proc Am Clin Oncol 21: (abstract 439)
25. Safra T (2003) Cardiac safety of liposomal anthracyclines. Oncologist 8(Suppl 2): 17-24
26. Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Storm G (2003) Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91: 115-122
27. Schiffelers RM, Metselaar JM, Fens MH, Janssen AP, Molema G, Storm G (2005) Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 7: 118-127
28. Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, de Leij LF, Molema G (2002) Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer 102: 469-475
29. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827-4833
30. 14C]-ZD6126 in patients with solid malignant tumors. Proc Am Soc Clin Oncol 22: (abstract 3083)
31. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436: 568-572
32. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11: 416-420
33. Siemann DW, Rojiani AM (2002a) Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54: 1512-1517
34. Siemann DW, Rojiani AM (2002b) Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53: 164-171
35. Siemann DW, Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60: 1233-1240
36. Taraboletti G, Micheletti G, Dossi R, Borsotti P, Martinelli M, Fiordaliso F, Ryan AJ, Giavazzi R (2005) Potential antagonism of tubulin-binding anticancer agents in combination therapies. Clin Cancer Res 11: 2720-2726
37. Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG (2005) Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 96: 10-18
38. Thorpe PE, Chaplin DJ, Blakey DC (2003) The first international conference on vascular targeting: meeting overview. Cancer Res 63: 1144-1147
39. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435
40. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK (2004) Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 31: 16-35
41. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP (2005) Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11: 835-842